A Phase 2 Non-randomized Open-label Study Examining the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer (CRPC)
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Jul 2019
Price : $35 *
At a glance
- Drugs Tomivosertib (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Sponsors Effector Therapeutics
- 16 Jul 2019 Planned End Date changed from 1 Apr 2022 to 1 Apr 2020.
- 16 Jul 2019 Planned primary completion date changed from 1 Feb 2019 to 1 Sep 2019.
- 16 Jul 2019 Status changed from recruiting to active, no longer recruiting.